Rational Therapeutic Drug Monitoring

JAMA: The Journal of the American Medical Association

Volumn 256, Issue 16, 1986, Pages 2227-2233

  Friedman, H ^a   Greenblatt, D J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACECAINIDE; CIMETIDINE; CLORAZEPATE DIPOTASSIUM; DESIPRAMINE; DIAZEPAM; DIGOXIN; DISOPYRAMIDE; GENTAMICIN; HALAZEPAM; IMIPRAMINE; LIDOCAINE; LITHIUM; NORDAZEPAM; PHENYTOIN; PRAZEPAM; PROCAINAMIDE; PROPRANOLOL; QUINIDINE;

BLOOD AND HEMOPOIETIC SYSTEM; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG DOSE; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVEY; THERAPY; TOPICAL DRUG ADMINISTRATION;

BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; BLOOD SPECIMEN COLLECTION; HUMAN; KINETICS; MONITORING, PHYSIOLOGIC; PHARMACEUTICAL PREPARATIONS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0022509339     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1986.03380160085025     Document Type: Article

References (47)

1. Koch-Weser J: Serum drug concentrations as therapeutic guides. N Engl J Med 1972;287:227-231.
2. Greenblatt DJ, Shader RI: Pharmacokinetics in Clinical Practice. Philadelphia, WB Saunders Co, 1985.
3. Greenblatt DJ, Koch-Weser J: Clinical pharmacokinetics. N Engl J Med 1975;293:702-705, 964-970.
4. Williams RL: Drug administration in hepatic disease. N Engl J Med 1983;309:1616-1622.
5. Hoyumpa AM, Branch RA, Schenker S: The disposition and effects of sedatives and analgesics in liver disease. Annu Rev Med 1978;29:205-218.
6. Dawson GW, Vestal RE: Smoking and drug metabolism. Pharmacol Ther 1982;15:207-221.
7. Powell JR, Donn KH: Histamine H2-antagonist drug interactions in perspective: Mechanistic concepts and clinical implications. Am J Med 1984; 77(suppl 5B):57-84.
8. Greenblatt DJ, Sellers EM, Shader RI: Drug disposition in old age. N Engl J Med 1982; 306:1081-1088.
9. Abernethy DR, Greenblatt DJ, Divoll M, et al.: Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 1981;217:681-685.
10. Friedman H, Greenblatt DJ, Burstein E, et al.: A population study of triazolam kinetics, abstracted. Clin Pharmacol Ther 1986;39:193.
11. Ochs HR, Greenblatt DJ, Harmatz JS, et al.: Serum digoxin concentrations and subjective manifestations of toxicity. Pharmacology 1980;20:149-154.
12. Morgan JP: Problems of mass urine screening for misused drugs. J Psychoactive Drugs 1984; 16:305-317.
13. Duhme DW, Greenblatt DJ, Koch-Weser J: Reduction of digoxin toxicity associated with measurement of serum levels. Ann Intern Med 1974;80:516-519.
14. Jusko WJ, Gretch M: Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev 1976;5:43-140.
15. Koch-Weser J, Sellers EM: Binding of drugs to serum albumin. N Engl J Med 1976;294:311-316, 526-531.
16. Greenblatt DJ, Smith TW, Koch-Weser J: Bioavailability of drugs: The digoxin dilemma. Clin Pharmacokinet 1976;1:36-51.
17. Blaschke TF, Rubin PC: Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet 1979;4:423-432.
18. Greenblatt DJ, Koch-Weser J: Intramuscular injection of drugs. N Engl J Med 1976;295:542-546.
19. DeBoer AG, deLeede LGJ, Breimer DD: Drug absorption by sublingual and rectal routes. Br J Anaesth 1984;56:69-82.
20. Greenblatt DJ, Divoll M, Harmatz JS, et al.: Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982;71:248-252.
21. Scavone JM, Greenblatt DJ, Friedman H, et al.: Enhanced bioavailability of triazolam following sublingual versus oral administration. J Clin Pharmacol 1986;26:208-210.
22. DeBoer AG, Moolenaar F, deLeede LGJ, et al.: Rectal drug administration: Clinical pharmacokinetic considerations. Clin Pharmacokinet 1982; 7:285-311.
23. Breimer DD: Rationale for rate-controlled drug delivery of cardiovascular drugs by the transdermal route. Am Heart J 1984;108:196-200.
24. Levy G: Clinical pharmacokinetics of salicylates: A re-assessment. Br J Clin Pharmacol 1980;10:285s-290s.
25. Lockwood GF, Albert KS, Gillespie WR, et al.: Pharmacokinetics of ibuprofen in man: I. Free and total area/dose relationships. Clin Pharmacol Ther 1983;34:97-103.
26. Levy RH, Moreland TA: Rationale for monitoring free drug levels. Clin Pharmacokinet 1984; 9(suppl 1):1-9.
27. Greenblatt DJ, Sellers EM, Koch-Weser J: Importance of protein binding for the interpretation of serum or plasma drug concentration. J Clin Pharmacol 1982;22:259-263.
28. Fröscher W, Burr W, Penin H, et al.: Free level monitoring of carbamazepine and valproic acid: Clinical significance. Clin Neuropharmacol 1985; 8:362-371.
29. Sellers EM: Plasma protein displacement interactions are rarely of clinical significance. Pharmacology 1979;18:225-227.
30. McElnay JC, D'Arcy PF: Protein binding displacement interactions and their clinical importance. Drugs 1983;25:495-513.
31. Gugler R, Shoeman DW, Huffman DH, et al.: Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest 1975;55:1182-1189.
32. Piafsky KM: Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980;5:246-262.
33. Wilder BJ, Serrano EE, Ramsay RE: Plasma diphenylhydantoin levels after loading and maintenance doses. Clin Pharmacol Ther 1973;14:797-801.
34. Greenblatt DJ, Bolognini V, Koch-Weser J, et al.: Pharmacokinetic approach to the clinical use of lidocaine intravenously. JAMA 1976;236:273-277.
35. Tomson T: Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol 1984;41:830-834.
36. Kelly HW, Murphy S: Efficacy of a 12-hour sustained release preparation in maintaining therapeutic serum theophylline levels in asthmatic children. Pediatrics 1980;66:97-102.
37. Thienes CH, Haley TJ: Clinical Toxicology, ed 4. Philadelphia, Lea & Febiger, 1964.
38. Marks V: Immunoassays for drugs, in Richens A, Marks V (eds): Therapeutic Drug Monitoring. New York, Churchill Livingstone Inc, 1981.
39. Blyden GT, Franklin C, Cho SI, et al.: Cyclosporine blood concentrations determined by specific versus nonspecific assay methods. J Clin Pharmacol 1986;26:367-371.
40. Divoll M, Greenblatt DJ: The admissibility of positive EMIT results as scientific evidence: Counting facts, not heads. J Clin Psychopharmacol 1985;5:114-116.
41. McBay AJ: Cannabinoid testing: Forensic and analytical aspects. Lab Management 1985; 23(Jan):36-41.
42. Sherma J: Gas chromatography, in Zweig G, Sherman J (eds): Handbook of Chromatography. Boca Raton, Fla, CRC Press Inc, 1972, vol 2.
43. Kabra PM, Morton LJ (eds): Liquid Chromatography in Clinical Analysis. Clifton, NJ, Humana Press, 1981.
44. Drayer DE: Pharmacologically active metabolites of drugs and other foreign compounds. Drugs 1982;24:519-542.
45. Atkinson AJ, Strong JM: Effect of active drug metabolites on plasma level-response correlations. J Pharmacokinet Biopharm 1977;5:95-109.
46. Potter WZ, Calil HM, Manian AA, et al.: Hydroxylated metabolites of tricyclic antidepressants: Preclinical assessment of activity. Biol Psychiatry 1979;14:601-613.
47. Friedman H, Ochs HR, Greenblatt DJ, et al.: Tissue distribution of diazepam and its metabolite desmethyldiazepam: A human autopsy study. J Clin Pharmacol 1985;25:613-615.